Form 8-K - Current report:
SEC Accession No. 0001193125-25-220830
Filing Date
2025-09-26
Accepted
2025-09-26 17:29:26
Documents
17
Period of Report
2025-09-23
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d898051d8k.htm   iXBRL 8-K 30686
2 EX-3.1 d898051dex31.htm EX-3.1 22450
7 GRAPHIC g898051new.jpg GRAPHIC 5106
8 GRAPHIC g898051sp6b.jpg GRAPHIC 1940
9 GRAPHIC g898051sp6c.jpg GRAPHIC 3712
  Complete submission text file 0001193125-25-220830.txt   237105

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA xoma-20250923.xsd EX-101.SCH 4580
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE xoma-20250923_def.xml EX-101.DEF 14855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE xoma-20250923_lab.xml EX-101.LAB 25344
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xoma-20250923_pre.xml EX-101.PRE 15953
20 EXTRACTED XBRL INSTANCE DOCUMENT d898051d8k_htm.xml XML 8003
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39801 | Film No.: 251351591
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)